LEXINGTON, Mass.--(BUSINESS WIRE)--TARIS today announced that it will present a late-breaking poster related to TAR-200 (GemRIS™), the company’s lead clinical program in bladder cancer, at the upcoming American Association of Cancer Research (AACR) Annual Meeting, April 14-18, 2018 in Chicago.
Poster presentation details are as follows:
|Significant cytotoxic and immumomodulatory effects of continuous low dose intravesical gemcitabine in rodent bladder tumor models|
|LBPO.IM01 - Late-Breaking Research: Immunology 1|
|April 16, 2018, 8:00 AM - 12:00 PM, Poster Section 45, Board #19|
About Muscle Invasive Bladder Cancer
Bladder cancer is the fifth most common neoplasm in industrialized countries, affecting roughly 2.7 million people worldwide. In the United States, there were an estimated 79,000 new cases and nearly 17,000 deaths in 2017; Muscle Invasive Bladder Cancer (MIBC) accounts for 20-25% of the newly diagnosed cases and the majority of disease-related mortality.
While some potentially curative treatments, including surgical organ removal and chemoradiation, are available, 40% or more of patients with MIBC are unfit to undergo these morbid procedures, or opt to not receive them.i Available treatment options for these patients are limited to palliative care.
About TAR-200 (GemRIS™)
TAR-200 is TARIS’s lead investigational program in bladder cancer, and is designed to release the chemotherapeutic agent gemcitabine continuously in the bladder for multiple weeks.
About TARIS Biomedical®
TARIS Biomedical® is building a unique therapeutically-focused urology company, developing targeted new treatments for millions of patients suffering from difficult-to-treat bladder diseases. We are advancing therapies for debilitating conditions, including bladder cancer and overactive bladder, enabled by continuous local dosing where it is needed. www.tarisbiomedical.com
i Gray, PJ. et al. Eur Urol, 2013, 63(5), 823 - 829